RxDoctor Payments Data

David Medford, MD

Ophthalmology · Morristown, NJNPI 1023079522

Payments from drug & device makers

$2,344in general payments, 2019–2025

Across 83 payments — averaging $28.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$744
  • Glaukos Corporation$420
  • Alcon$408
  • Sight Sciences, Inc.$195
  • Ocular Therapeutix, Inc.$106
  • NEW World Medical,inc.$100
  • plus $370 from 12 others

What the payments were for

  • Food & beverage$2,344100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,344 in reported general payments places this provider in the 60th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$421,110
Medicare patients
1,018
Services billed
4,287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost73$51,035
XiidraLifitegrast14$24,783
RestasisCyclosporine16$23,690
RocklatanNetarsudil Mesylat/Latanoprost26$20,502
CombiganBrimonidine Tartrate/Timolol29$15,646
TafluprostTafluprost/Pf25$10,962
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol26$6,782
Travoprost36$6,539
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat258$5,195
Latanoprost320$4,207
ZioptanTafluprost/Pf13$3,307
Brimonidine Tartrate14$2,915
Dorzolamide-TimololDorzolamide/Timolol/Pf23$2,857
Timolol Maleate165$2,683
Tobramycin-DexamethasoneTobramycin/Dexamethasone52$1,959

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$744$90,372118 claims
Aerie Pharmaceuticals, Inc.Rocklatan$29$20,50226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Morristown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →